Organovo (ONVO) is a medical research laboratory that designs and develops functional, three dimensional human tissue for research and therapeutic applications.
This means ONVO essentially 3-D prints things such as vascular smooth muscle cells, endothelial cells, and fibroblasts. The company can even develop full-on blood vessels.
And the technology has gained some solid attention…
Given the fact that drug-induced liver damage is one of the largest reasons drugs fail clinical trials, ONVO has previously been tasked to print miniature human “livers” for testing by several pharmaceutical companies.
Meanwhile, firms like L’Oreal (LRLCY) have used the company’s technology to create living human skin for product testing.
But, while this kind of technology is groundbreaking, the company is relatively small in size (with a $66 million market cap).
So, investors should be aware that this is a speculative investment. With that in mind, its low $7.60 share price suggests that if any major progress is made, shareholders could potentially make some serious gains.
The Alzheimer's Association estimates that, “caring for individuals with Alzheimer's will cost American society $20 trillion.”
Jim Cramer says a drug that could treat the disease “would be the biggest drug ever.”
The Wall Street Journal says the “financial benefits would be massive.”
One small biotech holds the key to a revolution in treating this dreaded disease.
Jeff Bezos, Goldman Sachs & a Big Pharma giant have invested billions into this unknown biotech.
And our research shows that anyone who gets in today could turn every $1,000 into $1.1 million.